Bivictrix’s BVX-002 shows tumor growth inhibition and regression in murine model of ovarian cancer
Bivictrix Therapeutics plc has announced promising initial in vivo data for BVX-002, its lead solid tumor bispecific antibody-drug conjugate (ADC) program. The preclinical study is investigating ...
Heart disease caused by damage to blood vessels is the leading cause of death worldwide. Arteries become clogged with fats and cholesterol when certain proteins in the body, known as lipoproteins, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback